The reduction of angiotensin II production and the synergestic effect of bradykinin in ACEIs enhances its cardio-protection effect by directly reducing IL-33 binding to sST2 and through the inhibition of TGF-β/MAPK/Smad signaling in RHD progression. This evidence concerns the gene IL33 and rheumatic heart disease.